Searched for
GENERIC LIRAGLUTIDE MARKET
Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...- Govt cracks down on GLP-1 drugs: Safety first amid weight-loss hypeIndia's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescriptio...
- Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas TambeBiocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management...
- Glenmark set to join peers in 'Semaglutide' pushGlenmark Pharmaceuticals is set to launch affordable versions of the popular anti-diabetes and obesity drug semaglutide. This move escalate...
- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Eris Lifesciences eyes ‘good’ share in semaglutide generics, says COOEris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims ...
- Obesity lab: India becomes ground zero for weight-loss drug raceIndia is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...
- Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and WegovyBiocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canad...
- Biocon plans $150-million capex in two yearsBiocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 mi...
- Buy Biocon, target price Rs 351: Axis SecuritiesAxis Securities recommends a Buy call on Biocon, setting a target price of Rs 351, indicating a potential 10% upside. The recommendation is...
- Biocon launches diabetes, obesity management drug in UKBiocon has launched Liraglutide, a drug for diabetes and obesity management, in the UK under the brand names Liraglutide Biocon and Biolide...
- Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is...
- How is India transforming the global biopharma landscape?In 2024, India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T therapy. ...
- Amid pollution woes, Asthma drug demand drives pharma retail market growth in NovemberIndia's pharmaceutical retail market rebounded in November with double-digit growth, fueled by increased demand for dermatological, cardiac...
- Biocon shares fall 6% after Q2 net profit dives 84%. What should investors do?Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...
- India to make drugs for diabetes, obesity under PLI by 2026, says reportIndia plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a govern...
- Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivotWeight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in gen...
- Nifty healthcare index stocks analysts suggest buying have potential upside of more than 19%Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a lo...
- Sajjala Bio to begin clinical trials on diabetes drugIn a statement, the Hyderabad-based company that reported Rs 15 crore of revenue last fiscal year, said it would soon take up clinical stud...
Load More
